TY - JOUR
T1 - Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 following the Largest Initial Epidemic Wave in the United States
T2 - Findings from New York City, 13 May to 21 July 2020
AU - Pathela, Preeti
AU - Crawley, Addie
AU - Weiss, Don
AU - Maldin, Beth
AU - Cornell, Jennifer
AU - Purdin, Jeff
AU - Schumacher, Pamela K.
AU - Marovich, Stacey
AU - Li, Joyce
AU - Daskalakis, Demetre
AU - Pacione, Vinny
AU - Abril, Cesar
AU - Chong, Elena
AU - Koehn, John
N1 - Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
PY - 2021/7/15
Y1 - 2021/7/15
N2 - Background: New York City (NYC) was the US epicenter of the spring 2020 coronavirus disease 2019 (COVID-19) pandemic. We present the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and correlates of seropositivity immediately after the first wave. Methods: From a serosurvey of adult NYC residents (13 May to 21 July 2020), we calculated the prevalence of SARS-CoV-2 antibodies stratified by participant demographics, symptom history, health status, and employment industry. We used multivariable regression models to assess associations between participant characteristics and seropositivity. Results: The seroprevalence among 45 367 participants was 23.6% (95% confidence interval, 23.2%-24.0%). High seroprevalence (>30%) was observed among black and Hispanic individuals, people from high poverty neighborhoods, and people in healthcare or essential worker industry sectors. COVID-19 symptom history was associated with seropositivity (adjusted relative risk, 2.76; 95% confidence interval, 2.65-2.88). Other risk factors included sex, age, race/ethnicity, residential area, employment sector, working outside the home, contact with a COVID-19 case, obesity, and increasing numbers of household members. Conclusions: Based on a large serosurvey in a single US jurisdiction, we estimate that just under one-quarter of NYC adults were infected in the first few months of the COVID-19 epidemic. Given disparities in infection risk, effective interventions for at-risk groups are needed during ongoing transmission.
AB - Background: New York City (NYC) was the US epicenter of the spring 2020 coronavirus disease 2019 (COVID-19) pandemic. We present the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and correlates of seropositivity immediately after the first wave. Methods: From a serosurvey of adult NYC residents (13 May to 21 July 2020), we calculated the prevalence of SARS-CoV-2 antibodies stratified by participant demographics, symptom history, health status, and employment industry. We used multivariable regression models to assess associations between participant characteristics and seropositivity. Results: The seroprevalence among 45 367 participants was 23.6% (95% confidence interval, 23.2%-24.0%). High seroprevalence (>30%) was observed among black and Hispanic individuals, people from high poverty neighborhoods, and people in healthcare or essential worker industry sectors. COVID-19 symptom history was associated with seropositivity (adjusted relative risk, 2.76; 95% confidence interval, 2.65-2.88). Other risk factors included sex, age, race/ethnicity, residential area, employment sector, working outside the home, contact with a COVID-19 case, obesity, and increasing numbers of household members. Conclusions: Based on a large serosurvey in a single US jurisdiction, we estimate that just under one-quarter of NYC adults were infected in the first few months of the COVID-19 epidemic. Given disparities in infection risk, effective interventions for at-risk groups are needed during ongoing transmission.
KW - SARS-CoV-2
KW - seroepidemiology
KW - seroprevalence
UR - https://www.scopus.com/pages/publications/85112124885
U2 - 10.1093/infdis/jiab200
DO - 10.1093/infdis/jiab200
M3 - Review article
C2 - 33836067
AN - SCOPUS:85112124885
SN - 0022-1899
VL - 224
SP - 196
EP - 206
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -